Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Intervention1: rybelsus: rybelsus 14 mg once a day orally for 6 months
Control Intervention1: dapagliflozin: 10 mg once a day orally for 6 months
Sponsors
surbhi gupta
Eligibility
Inclusion criteria
Inclusion criteria: both male and female are eligible Non pregnant patients with T2D above the age of 18 years with documented hepatic steatosis transient elastography CAP more than 275 db per m with the following criteria T2D patients with Hba1c more than 7 percent Ability and willingness to provide informed consent
Exclusion criteria
Exclusion criteria: age less than 18 years and more than 100 age Hba1c more than 10 percent Current treatment with GLP1RA Pioglitazone SGLT2i Saroglitazar History of congestive heart failure NYHA class 1 to 4 Irreversible medical conditions with predicted survival less than1 year Alcohol consumption more than 14 units per week for women and more than 21 units per week for men Severe hepatic impairment of any cause AST or ALT more than 5 times the upper limit of normal Evidence of other forms of liver disease including hepatitis B hepatitis C and autoimmune hepatitis History of use of drugs known to cause hepatic steatosis methotrexate amiodarone valproate steroids History of pancreatitis Family history of thyroid cancer Pregnant patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study and compare the effect of semaglutide and dapagliflozin over 6 months in reducing liver fat and fibrosis in patients with T2D and MASLD by using TE.Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To study and compare the effect of semaglutide and dapagliflozin on changes in liver indices: FIB-4, FAST, AGILE 3+score. 2. To study and compare the effect of semaglutide and dapagliflozin on changes in laboratory parameters (transaminases, FPG, HbA1c, UACR, lipid profile). 3. To study and compare the effect of semaglutide and dapagliflozin on changes in Body Composition Analysis (BCA). Timepoint: 6 months;1. To study and compare the effect of semaglutide and dapagliflozin on changes in liver indices: FIB-4, FAST, AGILE 3+score. 2. To study and compare the effect of semaglutide and dapagliflozin on changes in laboratory parameters (transaminases, FPG, HbA1c, UACR, lipid profile). 3. To study and compare the effect of semaglutide and dapagliflozin on changes in Body Composition Analysis (BCA). Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Ambrish Mithal
max hospital saket
Outcome results
None listed